Bride and groom in systemic inflammation - The bells ring for complement and Toll in cooperation

被引:33
作者
Barratt-Due, Andreas [1 ,2 ]
Pischke, Soeren Erik [1 ,2 ]
Brekke, Ole-Lars [3 ,4 ]
Thorgersen, Ebbe Billmann [1 ]
Nielsen, Erik Waage [5 ,6 ,7 ]
Espevik, Terje [8 ]
Huber-Lang, Markus [9 ]
Mollnes, Tom Eirik [1 ,7 ,10 ]
机构
[1] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Immunol, N-0424 Oslo, Norway
[2] Univ Oslo, Rikshosp, Oslo Univ Hosp, Div Emergencies & Crit Care Med, N-0424 Oslo, Norway
[3] Nordland Hosp, Dept Lab Med, Bodo, Norway
[4] Univ Tromso, Inst Med Biol, N-9001 Tromso, Norway
[5] Nordland Hosp, Dept Emergency Med, Bodo, Norway
[6] Nordland Univ, Bodo, Norway
[7] Univ Tromso, Fac Hlth Sci, N-9001 Tromso, Norway
[8] Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, N-7034 Trondheim, Norway
[9] Univ Ulm, Ctr Surg, Dept Orthoped Trauma Hand Plast & Reconstruct Sur, Ulm, Germany
[10] Nordland Hosp, Res Lab, Bodo, Norway
关键词
Complement; C5; CD14; Sepsis; SIRS; TUMOR-NECROSIS-FACTOR; SEVERE SEPSIS; INNATE IMMUNITY; UP-REGULATION; SEPTIC SHOCK; NON-SELF; CONTRACTILE DYSFUNCTION; COMBINED INHIBITION; DIRECTED THERAPY; TISSUE-INJURY;
D O I
10.1016/j.imbio.2012.07.019
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Attenuating the sepsis-induced systemic inflammatory response, with subsequent homeostatic imbalance, has for years been one of the main tasks in sepsis related research. Complement and the TLR family constitute two important upstream sensor and effector-systems of innate immunity. Although they act as partly independent branches of pattern recognition, recent evidence indicate a considerable crosstalk implying that they can either compensate, synergize or antagonize each other. Combined inhibition of these pathways is therefore a particularly interesting approach with a profound anti-inflammatory potential. In previous preclinical studies, we demonstrated that targeting the key molecules C3 or C5 of complement and CD14 of the TLR family had a vast anti-inflammatory effect on Gram-negative bacteria-induced inflammation and sepsis. In this review, we elucidate the significance of these key molecules as important targets for intervention in sepsis and systemic inflammatory response syndrome. Finally, we argue that a combined inhibition of complement and CD14 represent a potential general treatment regimen, beyond the limit of sepsis, including non-infectious systemic inflammation and ischemia reperfusion injury. (C) 2012 Elsevier GmbH. All rights reserved.
引用
收藏
页码:1047 / 1056
页数:10
相关论文
共 164 条
[1]   Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients [J].
Abraham, E ;
Laterre, PF ;
Garbino, J ;
Pingleton, S ;
Butler, T ;
Dugernier, T ;
Margolis, B ;
Kudsk, K ;
Zimmerli, W ;
Anderson, P ;
Reynaert, M ;
Lew, D ;
Lesslauer, W ;
Passe, S ;
Cooper, P ;
Burdeska, A ;
Modi, M ;
Leighton, A ;
Salgo, M ;
Van der Auwera, P .
CRITICAL CARE MEDICINE, 2001, 29 (03) :503-510
[2]   TLR accessory molecules [J].
Akashi-Takamura, Sachiko ;
Miyake, Kensuke .
CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) :420-425
[3]   Innate immunity and adjuvants [J].
Akira, Shizuo .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2011, 366 (1579) :2748-2755
[4]   Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a [J].
Ali, Hydar .
IMMUNOLOGY LETTERS, 2010, 128 (01) :36-45
[5]   The role of neutrophils in severe sepsis [J].
Alves-Filho, Jose C. ;
de Freitas, Andressa ;
Spiller, Fernando ;
Souto, Fabricio O. ;
Cunha, Fernando Q. .
SHOCK, 2008, 30 :3-9
[6]   Upregulation of complement inhibitors in association with vulnerable cells following contusion-induced spinal cord injury [J].
Anderson, AJ ;
Najbauer, J ;
Huang, WC ;
Young, W ;
Robert, S .
JOURNAL OF NEUROTRAUMA, 2005, 22 (03) :382-397
[7]   The Search for Effective Therapy for Sepsis Back to the Drawing Board? [J].
Angus, Derek C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (23) :2614-2615
[9]  
[Anonymous], 2011, MED LETT DRUGS THER, V53, P104
[10]  
[Anonymous], 2008, INTENS CARE MED, DOI [DOI 10.1007/s00134-007-0934-2, DOI 10.1007/s00134-008-1040-9]